ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma

These results indicate that overexpression of ADAMs may contribute to gastric cancer progression and that ADAM-17 is a downstream target of FoxM1. Overall, the present study highlights the potential for FoxM1 and ADAMs as potential therapeutic targets for patients with gastric carcinoma.